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ROSThe p53 tumor suppressor is the most frequently inactivated gene in cancer. Several mouse models
have demonstrated that the reconstitution of the p53 function suppresses the growth of established
tumors. These facts, taken together, promote the idea of p53 reactivation as a strategy to combat
cancer. This review will focus on recent advances in the development of small molecules which
restore the function of wild type p53 by blocking its inhibitors Mdm2 and MdmX or their upstream
regulators and discuss the impact of different p53 functions for tumor prevention and tumor erad-
ication. Finally, the recent progress in p53 research will be analyzed concerning the role of p53
cofactors and cellular environment in the biological response upon p53 reactivation and how this
can be applied in clinic.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Major efforts for the development of novel anti-cancer drugs are
currently focused on targeting oncogene addiction, whereas strate-
gies aimed to restore the function of the tumor suppressor p53 have
been much less popular so far, perhaps due to the fact that it was
unclear whether the loss of p53 function is required for the mainte-
nance of established tumors. Elegant in vivo studies using three
different approaches to engineer mice with ‘‘switchable’’ p53, dem-
onstrated that restoration of p53 leads to an impressive regression
of already developed tumors–lymphomas, soft tissue sarcomas
and hepatocellular carcinomas [1–3]. The important conclusion
from these studies is that tumors remain susceptible to the p53-
mediated tumor suppression. The absence of toxic effects in normal
tissues upon p53 reconstitution suggests that normal cells are not
signiﬁcantly affected upon p53 re-establishment achieved by non-
genotoxic treatment [4]. In contrast, it appears that tumor cells carry
the signals which support the growth suppression invoked by p53.
p53 is a potent tumor suppressor and is a subject of intensive
studies for more than 30 years (for a review, see [5]). It is well
established that p53 is a transcriptional factor activated by different
types of stresses which regulates the expression of genes involved
in control of cell cycle and cell death (reviewed in [6]). Activated
p53 can prevent the propagation of cells carrying oncogenic lesionsvia a multitude of pathways, i.e.: induction of growth arrest, senes-
cence or apoptosis, modulation of tumor stroma, angiogenesis and
metabolism, as well as the block of invasion andmetastasis [5]. This
explains why loss of p53 function is selected for during tumor
development, resulting in p53 inactivation in the majority of
human tumors. Indeed, the unbiased sequencing studies of thou-
sands of cancer genomes recognize the TP53 as the most frequently
mutated gene [7,8]. This fact, taken together with the conclusions
from the mouse in vivo experiments ﬁrmly support the notion that
restoration of p53 function in tumors could be an attractive and
tumor-cell speciﬁc strategy for treating cancer.
Reactivation of p53 appears to be feasible, since the p53 protein,
in contrast to many other tumor suppressors such as Rb or PTEN, is
usually expressed in tumors, although functionally inert. Different
strategies for the reconstitution of p53 function could be envisioned,
depending on the type of p53 inactivation. Re-folding ofmutant p53
in tumors carrying TP53 pointmutations appears to be an attractive
strategy [9,10]. In tumors expressing wild type p53 the promising
approach is to blockmajor p53 inhibitors,Mdm2andMdmX, or viral
E6 oncogene in HPV-driven cervical cancers. This review is focused
on p53 reactivation via inhibition of Mdm2 and MdmX.
2. Mdm2 and MdmX – major inhibitors of wild type p53 in
tumors
In the absence of TP53 mutations, the tumor suppressor func-
tion of p53 is frequently impaired due to a diverse alterations
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by Mdm4 gene). Mouse models provided a compelling evidence
that Mdm2 and closely related MdmX are the major negative reg-
ulators of p53. Genetically engineered mice lacking either Mdm2
or MdmX die in utero. Importantly, in the p53-null background
the embryonic lethality is completely rescued, underscoring the
fundamental role of Mdm2 and MdmX in p53 regulation [11–13].
Mdm2 can inhibit p53 via a number of mechanisms (reviewed
in [14]). The most studied is Mdm2 binding to the N-terminal
transactivation domain of p53 which blocks its transcription func-
tion [15]. Mdm2 also functions as a E3 ubiquitin ligase which pro-
motes either monoubiquitination of p53 leading to enhanced
nuclear export [16], or polyubiquitination of p53 that targets p53
for proteasomal degradation [17,18]. In addition, Mdm2 negatively
affects p53 mRNA translation [19]. While MdmX also binds the p53
N-terminus and blocks its transcriptional function, it does not pos-
sess an intrinsic E3 ligase activity [20] and is unable to target p53
for degradation. Mdm2 forms oligomers with itself or MdmX
through RING-ﬁnger domains; hetero-oligomerization of Mdm2
and MdmX renders a more efﬁcient E3 ligase activity towards
p53 [21]. This fact helps to explain the functional non-redundancy
of Mdm2 and MdmX observed in mouse models.
Human cancers frequently have elevated levels of Mdm2 lead-
ing to the inhibition of p53 function. This phenomenon has been
reported in sarcomas, gliomas, hematological malignancies, mela-
nomas, and carcinomas (reviewed in [22]).
Alterations leading to Mdm2 overexpression involve gene
ampliﬁcation (in 30% of sarcomas), elevated transcription,
increased mRNA stability, enhanced translation, and altered post-
translational modiﬁcations (reviewed in [23]). A single nucleotide
polymorphism at position 309 (SNP309) in the human Mdm2 P2
promoter, which creates a novel binding site for the transcriptional
activator Sp1, leads to an increased Mdm2 expression and attenu-
ates p53 function. This has been shown to accelerate tumor devel-
opment in humans [24].
In addition, a number of factors which control Mdm2/X activity
are deregulated in cancers. Loss of expression of the negative reg-
ulator of Mdm2 p14ARF, or enhanced activity of positive regulators
of Mdm2 Akt or Wip1, as well as other mechanisms, increase the
inhibitory function of Mdm2/X towards p53 [25].
3. Pharmacological rescue of wtp53 by prevention of Mdm2/X-
mediated inhibition
Several classes of small molecules which interfere with the inhi-
bition of p53 by Mdm2/X have been reported. Development and
properties of inhibitors of p53/Mdm2/X interaction have been
extensively reviewed in [26–28]. In brief, these molecules can act
via targeting Mdm2 or/and MdmX, or their upstream regulators,
or p53 itself (Fig. 1).
3.1. Blocking the p53 binding to Mdm2
The majority of small molecules developed so far which target
the p53/Mdm2 complex mimic p53 peptide which interacts with
Mdm2 and bind to the hydrophobic cleft in Mdm2, thus acting
by steric hindrance (Fig. 1). The ﬁrst discovered molecules of this
class are nutlins (cis-imidasoline compounds, developed by Hoff-
man-La Roche), followed by the development of spiro-oxindole
compounds (MI series, including MI-63, MI-219), and benzodia-
zepinediones [29–31]. p53 reactivation by nutlin has been inten-
sively studied by a number of labs. In different types of cancer
cells p53 becomes stabilized and activated by nutlin, leading to
the expression of p53 target genes, such as p21 and PUMA, fol-
lowed by the induction of growth arrest or apoptosis in cultured
cells and tumor suppression in human cancer xenografts in mice(reviewed in [26]). These studies provide the proof-of-concept of
p53 rescue by inhibiting Mdm2 and a strong evidence for the fea-
sibility of this strategy.
In fact, MDM2 inhibitors, along with Bcl-2 inhibitors, such as
ABT 263/Navitoclax developed by Abbott/Genentech, are currently
regarded as the most successful examples of pharmacological
inhibitors of protein–protein interaction (PPIs) [32]. The initial suc-
cess of nutlins encouraged many companies and academic labs to
design novel compounds blocking the p53 binding site in Mdm2.
A new potent compound of MI series, MI-888, has been recently
reported to induce a complete and sustainable regression of osteo-
sarcoma xenograft tumors with ampliﬁed Mdm2 without obvious
toxic effects [33].
Orally available nutlin analog RG7112 is the ﬁrst Mdm2 inhib-
itor which has been tested in clinic in patients with liposarcoma
and acute leukemia. In a proof-of-mechanism study of RG7112 in
liposarcoma patients, the majority of which had Mdm2 ampliﬁca-
tion, administration of RG7112 for 10 days induced p53 and its tar-
get p21 and lead to decreased tumor cell proliferation. These
molecular events have been associated with a stable disease in
14 out of 20 patients and a partial response in one patient. It has
to be noted though, that all patients experienced adverse effects,
some of which were serious, including neutropenia and thrombo-
cytopenia [34].
Second generation Mdm2 inhibitor developed by Hoffman-La
Roche, RG7388, has even higher potency and selectivity [35]. We
are currently witnessing an explosion of discoveries of compounds
blocking the p53-interacting pocket of Mdm2. Big pharmaceutical
companies, such as Novartis and Sanoﬁ, have several Mdm2 inhib-
itors in clinical development.
3.2. Targeting MdmX
The pro-apoptotic activity of Mdm2 inhibitors has been
observed only in a subset of cancer cell lines, which can limit their
application in clinic [36]. One of the factors which compromises
the efﬁciency of Mdm2 inhibitors is the overexpression of another
negative p53 regulator, MdmX. Mdm2 and MdmX regulate p53 in a
non-redundant fashion and act synergistically, as mentioned
above. Due to structural differences between the p53 binding
pockets in MdmX and Mdm2, molecules which inhibit Mdm2 have
low afﬁnity to MdmX. For example, nutlin has 400-fold lower
potency against MdmX than Mdm2 [37]. High levels of MdmX in
cancer cells make Mdm2 antagonists ineffective, therefore the
inhibition of both Mdm2 and MdmX is required for the full-scale
p53 activation [38,39]. Moreover, MdmX is upregulated in many
different cancers, such as retinoblastoma and tumors in breast,
lung and stomach [40,41]. MdmX plays a crucial role in p53 inac-
tivation in melanoma, cancer which is characterized by surpris-
ingly low incidence of p53 mutations [42]. This makes MdmX an
important target for cancer therapy.
Small molecule targeting p53 binding site in MdmX, SJ-172550,
has been discovered using high throughput biochemical screen
[43]. SJ-172550 does not kill cancer cells on its own, but has an
additive effect when combined with Mdm2 inhibitors.
Alternative approaches to inhibit MdmX, such as blocking its
mRNA, have been also developed. XI-100 blocks MdmX transcrip-
tion and acts synergistically with nutlin in cancer cell lines over-
expressing MdmX [44].
3.3. Blocking Mdm2 and MdmX simultaneously
Recent efforts have been focused on the identiﬁcation of dual
Mdm2/MdmX antagonists, i.e., ‘two in one’ inhibitors which can
offer an effective therapy for a more broad range of tumors. This
idea have been pursued by Vassilev and colleagues who identiﬁed
Fig. 1. Different mechanism of action of small molecules activating wild type p53. Compounds indicated in red are in clinical development.
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MdmX homo- or heterodimers which can not bind p53. This leads
to p53 activation, resulting in cell cycle arrest and apoptosis [45].
Novel pyrrolopyrimidine-based a-helix mimetics acting as dual
Mdm2/MdmX inhibitors in vitro have been developed which can
induce p53 and p21 in lung cancer cell line [46].
In silico screen lead to the identiﬁcation of lithocholic acid
(LCA), an endogenous steroidal bile acid. LCA binds to the p53
binding sites of both Mdm2 and MdmX with a ﬁvefold preference
for MdmX. These ﬁndings raise an interesting possibility that LCA
could be a natural ligand for Mdm proteins [47].
Our phenotypic screen led to the identiﬁcation of the thiophen-
derived small molecule RITA, which prevents p53 inhibition by
both Mdm2 and MdmX and induces apoptosis in a variety of cell
lines bearing wild-type p53 [48–50], see below for further details.
3.4. Inhibition of E3 ligase activity of Mdm2
Inhibitors of E3 ligase activity of Mdm2 towards p53 have been
discovered in biochemical screens, using decreased Mdm2 auto-
ubiquitination as a readout. First molecule of this class is HLI98C
[51], followed by a less genotoxic, more soluble and potent analog
HLI373 [52] and by the identiﬁcation of a natural compound sem-
pervirine [53]. These compounds stabilize p53, induce p53-depen-
dent transcription and selectively kill transformed cells expressing
p53.
Cell-based screen allowed to identify MEL23 and MEL24 com-
pounds which inhibit the E3 ligase activity of Mdm2/MdmX com-
plex, reduce the viability of cancer cells with wild type p53 and
synergise with DNA-damaging agents [54].
JNJ-26854165 (serdemetan) developed by Johnson&Johnson is
suggested to block p53 association with the proteasome, but the
exact mechanism has not been reported [55]. It demonstrated a
modest clinical activity and the ability to induce p53 in a phase I
clinical trial, although its administration has been associated with
toxic effects [56].
3.5. Stapled peptides
Early studies have identiﬁed potent peptides which sterically
block p53/Mdm2 complex, although they were not very promising
for clinical applications [57,58]. A new chemistry – such ashydrocarbon stapling of peptides – helps to resolve the major lim-
itations of peptides as drugs, i.e., unstable secondary structure and
proneness to proteolytic degradation. Stabilized alpha-helix-8
(SAH-8), modeled after Mdm2-binding peptide of p53, can prevent
Mdm2/p53 interaction and activate p53 in osteosarcoma cells [59].
Recently a high afﬁnity stapled peptide ATSP-7041 has been devel-
oped which blocks p53 complexes with both Mdm2 and MdmX
in vitro and in cells [60]. ATSP-7041 inhibits growth and induces
apoptosis in Mdm2-ampliﬁed osteosarcoma cells and in breast
cancer cells with high expression of MdmX and can suppress xeno-
graft tumor growth in mice. In addition, it has a favorable pharma-
cokinetics. This study provide a proof-of-concept that stapled
peptides can serve as potent and selective inhibitors of p53/
Mdm2/MdmX complex.
3.6. Compounds affecting upstream regulators of Mdm2/X
A number of factors acting upstream of Mdm2 could be targeted
in order to impair its stability, expression, or activity toward p53.
Mdm2 is negatively regulated by ribosomal proteins L5, L11 [61]
and several others which are released from nucleoli upon nucleolar
stress. Thus, compounds which can disrupt nucleoli, could inhibit
Mdm2 [62]. Indeed, low (nanomolar) doses of Actinomycin D
(Act D), compound which binds to GC-rich regions in DNA and dis-
rupts RNA synthesis, in particular ribosomal RNA biosynthesis [63],
induce p53 without signiﬁcant genotoxic effect. Strikingly, the gen-
ome-wide analysis of gene expression proﬁles show a high degree
of similarity between the patterns of genes induced by p53 in colon
cancer cells upon treatment with Act D and nutlin [64]. However, it
should be kept in mind that Act D activates p53 in normal cells as
well. For example, this highly potent compound can cause p53-
dependent reversible cell cycle arrest in normal keratinocytes [64].
Interestingly, a recent chemical library screen lead to the dis-
covery of several molecules which activate the p53 pathway and
kill cancer cells via interference with the DNA topology [65]. One
of the compounds, BMH-21, binds to GC-rich sequences, in partic-
ular in ribosomal DNA genes, leading to the inhibition of RNA Pol I
via proteasome-dependent degradation of Pol I subunit RPA194
and segregation of nucleolar proteins [66].
Small molecule CX5461 blocks rRNA biosynthesis by inhibiting
PolI transcription initiation step, and induces p53-dependent
apoptosis selectively in cancer cells [67].
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thereby inhibit p53/Mdm2 interaction [62]. In addition, roscovitine
can downregulate Mdm2 expression [68].
Inhibitors of nuclear export, such as a blocker of nuclear export
protein Crm1 Leptomycin B, are also candidate p53 activators.
Although Leptomycin B has been shown to induce apoptosis in
wild type p53-expressing cancer cells and has been tested in Phase
I clinical trial, its high toxicity precludes further clinical develop-
ment. Less toxic Crm1 inhibitor, compound 3, has been shown to
be more efﬁcient than Leptomycin B; it can inhibit cervical cancer
cell growth in vitro and in vivo [69].
Several posttranslational modiﬁcations have been shown to be
important for p53 activity, including acetylation (reviewed by
[70]). This opens a possibility to target enzymes involved in p53
modiﬁcations. One of such enzymes is deacetylase SirT1, a member
of sirtuin family, which removes activating acetyl groups from p53,
leading to its de-stabilization and loss of transcriptional activity
[71]. Sirtuin inhibitors have been identiﬁed which are able to sta-
bilize p53 and trigger its activation in cancer cells and inhibition of
tumor xenograft growth in vivo, including tenovins [72] and inauh-
zin [73].
Most of commonly used anticancer chemotherapeutics are DNA
damaging agents, whose potential is limited by severe side effects
and increased risk of secondary malignancies. However, several
DNA-targeting compounds such as low doses of Act D or BMH-21
mentioned above are non-genotoxic, but still are the potent killers
of cancer cells, often engaging p53. Other examples of such mole-
cules are well-known anti-malaria drug quinacrine and its opti-
mized follow up derivatives curaxins, which activate p53, inhibit
NF-kB and kill renal cell carcinoma cells in vitro and in vivo [74].
Further studies have shown that curaxins are non-genotoxic DNA
intercalators which act by affecting the chromatin remodeling
complex FACT (FAcilitates Chromatin Transcription), commonly
deregulated in cancer [75,76]. The proposed mechanism of action
involves ‘‘chromatin trapping’’ of FACT which results in the inhibi-
tion of NF-kB, as well as activation of p53 by FACT-associated
casein kinase 2 [75]. Potent anticancer activity of quinacrine and
curaxines in human tumor xenografts grown in mice promote
the idea of developing DNA intercalating/chromatin modifying
compounds as effective and safe anticancer drugs. This view is sup-
ported by recent testing of CBL0102, or quinacrine, in advanced
cancer patients with liver metastases performed by Cleveland Bio-
labs, Inc and Incuron, LLC. Phase I clinical trial demonstrated a
favorable pharmacological properties and mild side effects. Curax-
in CBL0137 is currently being tested in Phase I trials as well.
3.7. p53-Targeting compounds
We have identiﬁed a small molecule RITA (reactivation of p53
and induction of tumor cell apoptosis), which prevents p53/
Mdm2 interaction, induces p53 accumulation and transcriptional
activity and triggers p53-dependent apoptosis in tumor cells of a
different origin in vitro and in mice [48,77–79]. RITA was the ﬁrst
compound shown to bind the p53 N-terminus (residues 1-63). Our
studies provided proof-of-principle that a small molecule can bind
p53 N-terminus without hindering the transcriptional function of
p53. RITA triggers a conformational shift preventing p53’s interac-
tion with its negative regulators such as Mdm2 and others [48].
Notably, RITA induces the proteasome-dependent degradation of
MdmX protein via downregulation of Wip1 phosphatase, which
makes it highly efﬁcient in killing cells with overexpressed MdmX
[50].
Our ﬁnding that RITA induces a conformational change in p53
encouraged us to test whether it can restore the activity of mutant
p53. We found that RITA suppresses the growth and induces apop-
tosis in a p53-dependent manner, along with the induction of p53target genes, in a variety of mutant p53 carrying cell lines of differ-
ent origin [77,79]. These ﬁndings promote the idea of developing
compounds capable of simultaneously targeting wild type and
mutant p53.
Notably, at least some mutant p53-reactivating compounds
which interact with the p53 DNA-binding domain (DBD), such as
a synthetic peptide CDB3 and small molecules CP-31398 and
SCH529074, can also reactivate wild type p53 by interfering with
Mdm2-mediated degradation [80,81]. It is possible that they pre-
vent the docking of the central domain of Mdm2 to p53 DBD,
which is required for the efﬁcient ubiquitination of p53 by
Mdm2 [82]. Alternatively, these compounds might block other fac-
ets of Mdm2-mediated inhibition of p53. The mechanisms of acti-
vation of wild type p53 by two other mutant p53-reactivating
molecules, PRIMA-1Met (APR-246) [9] and p53R3 [83], are currently
less clear. Intriguingly, PRIMA-1MET/APR-246 activates wild type
p53 transcriptional activity and induces p53-dependent apoptosis
in melanoma cells in vitro and in vivo without apparent impact
on p53 level or stability [84] nor on Mdm2 or E6-mediated ubiqui-
tination of p53 [80].
Dual targeting of mutant and wild type p53 appears to be highly
beneﬁcial, since recent studies demonstrate that treatment with
nutlin creates a selective pressure for p53 mutations in different
types of cancer leading to resistant clones, which in some cases con-
tributes tomultidrug resistance [85,86]. Themechanism of simulta-
neous reactivation of mutant and wild type p53 by small molecules
remains elusive in most cases. Further elucidation of the structural
features of the full length p53 might help to understand their mode
of action. p53 has proven to be a challenge for structural biologists
due to its high conformational ﬂexibility. However, several impor-
tant achievements have been reported [87,88].4. Tumor suppression by p53: prevention vs eradication
Induction of the apoptosis, growth arrest or senescence upon
p53 activation by stress results in the elimination of mutated or
damaged cells [5]. p53 binds to its consensus sequences in the pro-
moters of target genes and acts as a transcriptional activator of
expression of multiple pro-apoptotic factors (Puma, Noxa, Bax,
Fas, etc.), or cell cycle arrest genes (p21, BTG2, etc.). In addition,
p53 can repress transcription of anti-apoptotic and survival factors
(i.e., BCL-2), as well as cell cycle-promoting genes (Cdc25A, Cyclin
B). Interaction of p53 with Bcl-2 family proteins in cytoplasm can
trigger apoptosis in a transcription-independent way (reviewed
in [5]. It is widely accepted that these activities represent a clear
mechanism of p53-mediated tumor suppression.
Reconstitution of p53 using several elegant in vivo models have
proven that restoration of p53 confers increased survival of mice
with established tumors in El-myc lymphoma model and leads
to the regression of established tumors due to the induction of
apoptosis or senescence in autochthonous lymphoma and sarcoma
model and liver carcinoma model [1–3].
Yet, the prevailing view that the induction of apoptosis or
growth arrest is the core of p53 tumor suppressor function has
been recently challenged by in vivo studies. Several groups have
shown that the transgenic mice expressing mutants compromised
for cell cycle arrest, senescence and apoptosis are still able to func-
tion as tumor suppressors.5. Involvement of non-canonical p53 functions in tumor
suppression by p53
Despite the inability of transactivation-deﬁcient mutant
p5325,26 (L25Q; W26S) to activate classical p53 target genes p21,
Noxa, and Puma and to trigger cell cycle arrest, apoptosis and
Fig. 2. Different activities contribute to tumor prevention and tumor eradication by
p53. Regulation of DNA repair and metabolism as well as antioxidant response are
more important for tumors prevention (indicated in green) whereas the induction
of apoptosis and immune surveillance are more important for tumor eradication
(indicated in blue). Induction of senescence, autophagy and growth arrest might
have opposite effects on p53 tumor suppression, depending on the context
(indicated in purple).
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tial tumor suppressor activity when expressed in mice, as found by
Attardi and her colleagues. Interestingly, p5325,26 can regulate the
expression of a subset of ‘non-classical’ genes, suggesting that
other mechanisms can contribute to the tumor suppression by
p53 [89]. Moreover, these data support the notion that the induc-
tion of Puma, Noxa and p21 culminating in apoptosis or growth
arrest is important for the response to acute DNA damage, but
not to non-genotoxic oncogenic stress, thus distinguishing
between these two different p53 functions. Data obtained earlier
in other mouse models, also points out to the idea that the
response to acute DNA damage by the induction of apoptosis might
differ from the tumor suppression pathway evoked by p53 in
response to oncogene activation [90].
It should be noted, however, that the transcriptional transacti-
vation function of p53 is necessary for tumor suppression, since
transactivation-dead mutant p5325,26,53,54 (carrying mutations in
transactivation domain 1, L25Q;W26S, as well as inactivating
mutations in transactivation domain 2, F53Q;F54S) was com-
pletely unable to suppress carcinogenesis in several models [91].
Expression of another p53 mutant defective in the induction of
pro-apoptotic target genes and apoptosis – p53RR mutated at resi-
due E177 (corresponding to human E180 and preventing coopera-
tive DNA binding by p53) – lead to an increased tumor incidence in
mice compared to control wild type mice. However, despite the
inability to eliminate cancerous cells by apoptosis, this mutant
p53 was still able to suppress the development of T-cell lympho-
mas. It is possible that the ability of p53RR to limit glycolysis and
ROS accumulation via induction of expression of Gls and Dram
underlies its partial tumor suppression [92].
Furthermore, in spite of the abrogation of p53-mediated cell
cycle arrest, apoptosis and senescence, mice carrying p53KR
mutated at K117R, K161R, K162R which abolishes its acetylation,
do not succumb to the formation of early-onset spontaneous
tumors. Taking into account that p53KR can activate the expression
of metabolic target genes Gls2 and Tigar, it is possible that the
regulation of energy metabolism and ROS production could play
a crucial role in the tumor suppressor function by p533KR [93].
To test the involvement of growth arrest and apoptosis in
p53-mediated tumor suppression, Strasser and his colleagues gen-
erated the triple knockout mice lacking p21, Puma and Noxa. Cells
derived from these mice are resistant to p53-dependent apoptosis,
cell cycle arrest and senescence upon DNA damage. Notably, these
mice are not predisposed to the early onset of spontaneous tumors,
in contrast to p53-null mice. The authors suggest that the ability of
p53 to regulate DNA repair might be critical for the tumor preven-
tion by p53 [94].
In summary, several recent in vivo studies suggest that the
canonical p53 responses do not fully explain p53-mediated tumor
suppression. However, one important distinction should be made
between these models, which are investigating the development
of tumors and the ones which address the tumor eradication upon
p53 reconstitution in already developed tumors. Restoration of p53
in established tumors suppresses them by induction of apoptosis
or senescence, as clearly demonstrated in seminal papers
mentioned above. In contrast, in those transgenic mouse models
which investigate the development of tumors in the absence of
p53-dependent apoptosis and senescence, the question of tumor
prevention by p53 has been addressed. Thus, the two branches of
p53-mediated tumor suppression, tumor prevention and tumor
eradication, probably require different, albeit partially overlapping,
set of p53 functions (Fig. 2).
Indeed, anti-oxidant function of p53 is particularly important
for the prevention of lymphomas [95]. Treatment of p53-null
embryos in utero with anti-oxidants signiﬁcantly decreased
genomic instability, thus diminishing the chance for oncogenicmutations [95]. The ability of p53 to induce anti-oxidant genes,
such as sestrins, together with well documented plethora of
p53-mediated responses that facilitate DNA repair [96] appears
to be essential for the control of genomic integrity by p53, serving
to prevent oncogenic alterations.
Recent discovery that a whole set of genes involved in autoph-
agy is regulated by p53 [97], in addition to previously identiﬁed
DRAM [98], suggests that this facet of p53 activity might be
involved in tumor suppression. However, the role of autophagy
in tumor suppression appears to be very much dependent on a
context. Several recent studies suggest that the development of
breast carcinoma, non-small-cell lung cancer and pancreatic carci-
nomas in mouse models is more efﬁciently impeded by p53 in the
absence of essential autophagy factors, such as Becn-1, Atg7, or
Atg5 [99–101]. It will be critical to elucidate more thoroughly
the role of autophagy in p53-dependent tumor suppression, since
it might contribute to cancer cell survival and promote resistance
to anti-cancer therapies in some contexts.
Emerging is another non-canonical function p53 – facilitation of
immune surveillance of cancer. p53-Deﬁciency in intestinal epithe-
lial cells leads to an increasing inﬂammatory response, associated
with enhanced EMT and tumor invasion [102]. Tumor regression
upon p53 restoration in liver carcinoma has been found to be pro-
moted by the inﬁltration of innate immune cells [3]. This is due to
the production of cytokines by senescent tumor cells, which recruit
predominantly tumor suppressor M1 macrophages. In contrast,
cytokines produced by p53-deﬁcient tumor cells induce tumor-
promoting M2 macrophages [103]. Moreover, induction of expres-
sion of some p53 target genes can enhance the susceptibility of
tumor cells to immune system. Two independent studies, includ-
ing ours, identify ULPB2, encoding a ligand for NK cell activating
receptor NKG2D, as a new p53 target gene induced upon the phar-
macological reactivation of p53 in tumor cells. Expression of ULBP2
enhances the NK cell-mediated killing of tumor cells of a different
origin [104,105]. Toll-like receptor 3 (TLR3), a crucial innate
immune receptor, has been identiﬁed as a target gene of p53, sug-
gesting that p53 can potentiate interferon-alpha-induced apopto-
sis [106]. p53 can also promote cell surface expression of major
histocompatibility complex I via regulation of endoplasmic reticu-
lum aminopeptidase 1 [107].
In summary, it appears that some of p53 biochemical activities
might be required for the prevention of tumor formation, whereas
others are more important for the eradication of already formed
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of tumors and, perhaps ageing, small molecules could be developed
which speciﬁcally enhance the ‘‘prevention’’ function of p53,
whereas to eliminate already established tumors we should apply
small molecules activating ‘‘eradication ’’ function of p53 .6. p53: To kill or not to kill
Rigorous efforts that have been dedicated to development of
Mdm2/MdmX inhibitors for cancer therapy are starting to be trans-
lated into clinic; a number of clinical trials are being performed, as
mentioned above (Fig. 1). It is therefore of utmost importance to
understand which functional aspects of p53 these compounds acti-
vate. Reactivation of p53 tumor eradication function – i.e., apopto-
sis – in established cancers is the goal of p53-based therapies.
However, p53-mediated apoptosis in normal tissues is the cause
of pathological loss of cells upon chemotherapy, neurodegenerative
diseases, stroke and ischemia; it might also contribute to ageing [5].
Although mouse models have demonstrated that tumor cells have
higher propensity to die upon p53 restoration, the molecular basis
for the phenomenon needs to be elucidated (see below for more
discussion).We need to ﬁnd out how tomanipulate p53 to promote
death selectively in tumor, but not in normal cells.
Recent study points out that the induction of senescence by p53
might impair the response to chemotherapy in clinic in breast
cancer patients [108]. However, in some types of tumors, as for
example in acute promyelocytic leukemia (APL) driven by the pro-
myelocytic leukemia (PML)–retinoic acid receptor-a (PML–RARA)
fusion protein, induction of senescence by p53 is beneﬁcial for
patients [109]. Thus, it appears that the induction of senescence
can affect anti-cancer therapy in quite opposite ways. The outcome
probably depends on the type of factors secreted by senescent
cells, which in turn determines the type of immune cells which
are recruited to tumor. It needs to be investigated how the
secretome of senescent cells is regulated. Further, triggering p53-
mediated growth arrest, DNA repair, and/or antioxidant response
in established cancers is not desirable since it will counteract
chemo- or radiotherapy. Yet, these functions of p53 can prevent
tumor formation. Thus, we need to rigorously determine the mech-
anisms of p53 life/death decision if we are to clinically exploit
drugs activating p53 in different types of cancer.Fig. 3. p53 can trigger different responses, leading to different biological outcomes.
However, the mechanisms which control p53’s choice of life/death decisions are
still unclear.7. Mechanisms of p53-mediated cell fate decisions
In order to harness p53 activities, it is crucial to meticulously
investigate the mechanisms by which p53 induces its vast range
of responses. p53 could be envisioned as a complex protein assem-
bly that remodels itself in a different way depending on a type of
stimulus and cellular environment, leading to different biological
outcomes. In essence, to understand p53 is to understand how its
interaction with proteins and, thus DNA, is controlled.
There are a lot of questions to address concerning the mecha-
nisms of differential transcription programs elicited by p53 for
triggering distinct biological outcomes. p53 response could be
determined by a number of factors, such as p53 posttranslational
modiﬁcations, cooperativity of binding to DNA, levels and duration
of its induction, and binding to its cofactors. In particular, it is not
clear whether it is p53 in vivo promoter selectivity that sets off dif-
ferent transcription programs. Our analysis of genome-wide chro-
matin occupancy by p53 using ChIP-seq revealed the ‘‘p53 default
program’’, i.e., the pattern of major p53-bound sites that is similar
upon p53 activation by nutlin3a, RITA or 5-FU in breast cancer cells,
despite of different transcriptional programs and biological
outcomes triggered by these compounds [110]. Thus, our study
suggests that p53 cofactors, but not the selective binding of p53to promoters, play a key role in the differential regulation of target
genes by p53. Therefore, the grand challenge of p53 research is to
identify cellular cofactors as well as small molecules that can
switch p53 transcriptional and biological responses in a desired
way (Fig. 3).
In spite of numerous studies, it still remains elusive, which fac-
tors direct p53 to a certain transcriptional program. We are just
beginning to get a deeper understanding of at least some mecha-
nisms governing different p53 activities. p53 is regulated by
numerous posttranslational modiﬁcations, such as phosphoryla-
tion, acetylation, ubiquitination, neddylation, sumoylation and
methylation (reviewed in [111]). For example, phosphorylation at
Ser46 by HIPK2, as well as acetylation at Lys120 by Tip60 facilitates
the transcriptional activation of pro-apoptotic targets by p53
[112,113]. Posttranslational modiﬁcations affect p53’s interactions
with its numerous binding partners which, in turn, differentially
modulate p53-induced transcriptional programs and thus biologi-
cal outcome. Studies that have looked into p53 interactions with its
partners have been well reviewed [5,114]. Some examples of cofac-
tors which cooperate with p53 in induction of cell cycle arrest
genes include Hzf1, Brn3A, and hnRNP K [5,49,115]. BRCA1, as well
as Ref-1 upon induction by selenium methionine, promote the
induction of DNA repair genes [116,117]. In contrast, ASPP cooper-
ates with p53 in activation of pro-apoptotic targets [118]. We have
recently identiﬁed Sp1 as an important cofactor for the apoptosis
induction by p53 [110].
In summary, p53-induced biological outcomes are dictated by a
number of collaborating or antagonizing factors and their combi-
nations, making it a daunting task to predict the p53 response in
different settings. Compounds activating p53 could serve as an
excellent molecular tools to address these crucial questions of
p53 biology.
8. Small molecules as research tools to address the p53 choice of
transcriptional programs
To investigate the molecular mechanisms affecting p53 out-
comes we have used two small molecules, nultin and RITA, which
induce growth arrest or apoptosis, respectively, in several cancer
cell lines, such as HCT116, MCF7 and U2OS. Both compounds inhi-
bit the p53/Mdm2 interaction, albeit targeting different proteins:
whereas nutlin, as described above, blocks the p53-binding pocket
in Mdm2, RITA binds to p53 and induces a conformational shift
making p53 recognition by Mdm2 inefﬁcient [29,48]. Further, it’s
important to mention that the levels of both Mdm2 and MdmX
eventually subside after RITA treatment [119–121], which is essen-
tial, since the level of MdmX determine the sensitivity of cells to
nutlin [122,123]. Although the mechanisms underlying the
decreased levels of Mdm2 and MdmX are only partially
understood, these studies suggest that certain branches of the
negative feedback loop induced by p53 are relieved after RITA. In
contrast, the binding of nutlin to Mdm2 stabilizes the protein
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induction of Mdm2 mRNA (as a consequence of Mdm2 transactiva-
tion by p53) it leads to a fast decrease of p53 levels upon removal
of the compound [124].
Data mentioned above suggest that the disruption of p53/
Mdm2 complex is not the sole effect of small molecules: along
with the prevention of Mdm2/p53 complex, they might also differ-
ently affect other events. Nutlin has been shown to act as an allo-
steric agonist of Mdm2 by inducing a conformational change in the
acidic domain of Mdm2 which facilitates p53 ubiquitination [82].
Further, proteomics screen identiﬁed nucleophosmin (NPM) as a
predominant partner of nutlin-bound Mdm2 [125]. In line with
the notion that nutlin affects Mdm2 interactome is the ﬁnding that
Mdm2 bound by nultin targets for the degradation HIPK2, kinase
facilitating p53-mediated induction of pro-apoptotic genes [121].
While binding of nultin changes the repertoire of Mdm2-binding
partners, RITA affects the p53 interactome (for a review, see
[25]). We found that Mdm2 released from p53 upon RITA can tar-
get for degradation itself and several of its substrates, including
those important for p53-mediated growth arrest: p53 cofactor
hRNP K and cdk inhibitor p21, but not HIPK2, thus contributing
to the switch from growth arrest to cell death [49].
9. Transcriptional repression vs transcriptional activation
Expression of survival factors blocking apoptosis downstream
of p53, such as anti-apoptotic Mcl-1 or Bcl-2 can block death-
inducing signals, resulting in growth arrest upon p53 activation
[126,127]. We found that p53 can confer the transcriptional
repression of major proliferative and survival factors upon RITA
resulting in rapid decline of the key components of the IGFR-
PI3K-Akt pathway, c-Myc, Mcl-1 and survivin [128]. This ablates
pro-proliferative and survival pathways, reducing the cancer cell’s
ability to counteract pro-apoptotic signals. The same degree of
repressed survival factors was not observed upon nutlin; however,
the combination of nutlin with depletion of Mcl-1 or c-Myc acted
synergistically to induce apoptotic response.
Notably, our data suggest that the induction of pro-apoptotic
genes and the repression of survival genes may require distinct
cofactors and/or posttranslational modiﬁcations of p53 [128].
While p53 transactivation function is relatively well understood,
there is still much to learn about the molecular mechanisms of
p53-mediated transcriptional repression [129]. p53 can repress
genes indirectly, as for example via long non-coding RNAs [130]
or p21 [131]. However, p21 is depleted upon p53 activation by
RITA [49]. Moreover, the repression of a number of genes by p53
upon RITA coincides with p53 binding to its consensus sites in
the promoters of these genes, suggesting a direct regulation by
p53 [110,128].
Our search for factors which facilitate the transcriptional
repression by p53 has implicated JNK in repression of pro-survival
genes Mcl-1, eIF4E, PIK3CA and PIK3CB [132]. Interestingly, we
found JNK to be a crucial factor which can convert p53 from a
transactivator to a repressor of some genes involved in negative
regulation of p53, such as PPM1D, encoding phosphatase Wip1
(wild type p53 induced protein1) and MdmX. Establishment of
JNK-p53 positive feedback loop and inhibition of p53-Wip1 nega-
tive feedback loop result in enhanced and sustained p53 activation,
which produces a robust apoptotic outcome [132].
10. Possible mechanisms of tumor-selective growth
suppression by p53
The risk of inhibiting Mdm2 comes from the fact that a sudden
activation of p53 in normal tissues might have undesirable toxiceffects in the Mdm2-null background [133]. However, studies
using xenograft models in mice demonstrated that tumor sup-
pressing doses of nutlin, RITA, MI-219 and stapled peptide ATSP-
7041 do not cause weight loss and are well tolerated
[29,48,60,134]. A number of studies point towards the ability of
p53 to kill cancer cells without detrimental effects in normal cells
in vitro and in vivo [135]. However, the molecular pathways by
which reconstituted p53 becomes pro-apoptotic selectively in
malignant tumors have not been deﬁned yet and are a subject of
intensive studies.
It has been reported that ampliﬁed MAPK signaling in aggres-
sive lesions supports the suppression of malignant tumors by
p53 upon its reconstitution [136,137]. Recent in vivo studies iden-
tify MKK7-JNK signaling as a crucial component that senses onco-
gene activation and links the oncogenic stress to p53-mediated
tumor suppression [138]. The question remained though, how
oncogenic stress is sensed by MKK7-JNK and how JNK modulates
the p53 function.
Deregulation of tumor suppressor and oncogenic pathways in
cancer frequently leads to different types of stresses experienced
by cancer cells, including replication stress, proteotoxic stress,
metabolic stress and an increased accumulation of reactive oxy-
gen species (ROS) (for review, see [139]). Our recent study sug-
gest that elevated ROS in malignant tumors might provide an
activating signal to p53 via JNK, which in turn facilitates p53
transcriptional activity, in particular, the transcriptional repres-
sion of survival genes [132]. It is tempting to speculate that the
enhanced and sustained p53 activity achieved due to high level
of ROS and JNK activation may constitute one of the reasons for
the selective elimination of advanced cancers by reinstated p53,
observed in mouse models. The relative contribution of the
ROS/MAPK pathway in oncogenic signaling and preferential sup-
pression of malignant tumors by p53 is an interesting subject
for future studies.
11. Combination therapy
The multi-gene nature of cancer suggests that the ablation of a
single target is unlikely to produce a sustained effect. Targeting
two or more unique alterations in cancer cells to produce synthetic
lethality appears to be a more feasible approach to achieve thera-
peutic activity and selectivity and to prevent the development of
drug resistance. One of the important biochemical differences
between normal and cancer cells is a decreased capability of cancer
cells to buffer high ROS levels. While increased ROS production
contributes to tumorigenesis, it must be restrained even in cancer
cells if they are to avoid the damaging effects of ROS on vital intra-
cellular macromolecules [140]. Therefore, cancer cells with
increased burden of oxidative stress are likely to be more vulnera-
ble to damage by further ROS insults [141,142].
We have previously shown that in addition to inhibiting p53/
Mdm2 interaction, small molecule RITA confers inhibition of
TrxR1, one of the key enzymes which keeps ROS balance [143].
Our study suggests that the dual targeting of p53 and TrxR1 by
compounds such as RITA leading to ROS induction, or a combina-
tion of p53 reactivating compounds with inhibitors of cellular
anti-oxidant systems confers synthetic lethality [132]. Indeed, we
showed that growth arrest/senescence by nutlin could be switched
to apoptosis upon low dose of TrxR inhibitor auranoﬁn [132].
Simultaneous targeting of p53 and cellular antioxidant system
might allow to maximally exploit the p53-mediated tumor sup-
pression as a therapeutic strategy.
Nutlin has been shown to synergize with a number of
chemotherapeutic drugs including those targeting tubulin (vin-
blastine), DNA-damaging agents (doxorubicin), S-phase agents
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disadvantage of combining p53 reactivation with chemotherapy
is the augmentation of p53 activation both in cancer and in normal
tissues which can produce side effects. In fact, the contribution of
p53 to tissue toxicity upon chemotherapy prompted researchers
to develop small molecules inhibiting p53 to minimize side effects
[144,145].
Combination therapy might help to avoid the development of
resistance, such as for example, mutations in Mdm2 [146]. As men-
tioned above, it was found in several studies that treatment with
nutlin leads to selection of p53 mutants, which could accumulate
while Mdm2 is inhibited and in addition to be a cause of resistance.
Mutant p53 might even display gain-of-function activities promot-
ing tumor growth. Therefore it could be a promising strategy to
combine wild type reactivating compounds with those restoring
mutant p53 function, such as PRIMA-1MET/Apr246.
Search for the rational combinations of drugs which can pro-
duce synergy when combined with Mdm2 inhibitors, revealed that
low doses of CDK inhibitors promote apoptosis induction when
combined with nutlin [147]. siRNA screen against known human
kinases pinpointed to several pathways, including the MAP kinase
pathway and the sphingosine kinase pathway whose inhibition
may synergize with nutlin [148]. Genome-wide short hairpin
RNA screen for genes that are lethal in combination with p53 acti-
vation by nutlin has identiﬁed the inhibition of ATM and MET
kinases as means to convert the cellular response by nutlin from
cell cycle arrest into apoptosis in diverse cancer cell types [149].
Cyclotherapy, i.e., induction of growth arrest in normal tissues
thus protecting them from the effects of chemotherapeutics while
unshielding cancer cells is an emerging strategy to minimize side
effects. Since normal cells have an intact p53 pathway, low doses
of non-genotoxic p53 activators, such as nutlin or actinomycin D
result in a reversible cell cycle arrest, making them immune to
drugs targeting actively proliferating cells, such as Aurora kinase
inhibitor. In contrast, cancer cells carrying mutant p53 continue
to proliferate and are selectively killed [150,151]. In vivo study
supports this idea by showing that nutlin-3 pretreatment protects
mice from neutropaenia induced by the Polo-Like-Kinase-1 (PLK-1)
inhibitor BI2536 [152]. Thus, cyclotherapy is a promising strategy
to improve the therapeutic window of classic chemotherapeutic
agents by non-genotoxic p53 activators that can induce a mild
‘cytostatic’ effect in normal tissues.
12. Concluding remarks
Reactivation of p53 is a very promising anti-cancer strategy
which is currently being tested in clinic. There are a number of crit-
ical issues which remain to be addressed in order to apply p53-
reactivating drugs for the beneﬁt of patients. We still have to ﬁnd
out which biomarkers can predict the response to p53-targeted
therapy, the mechanisms of intrinsic and acquired resistance and
possible side effects. The efﬁcient implementation of p53-targeting
treatments into clinical practice requires thorough understanding
of mechanisms governing p53 response in cancer cells. Small mol-
ecules could serve as valuable tools to address these burning ques-
tions of p53 biology.
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